BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 22968732)

  • 1. [Translational research and diagnostics of melanoma].
    Rüschoff J; Kleinschmidt M; Middel P
    Pathologe; 2012 Nov; 33 Suppl 2():291-5. PubMed ID: 22968732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [New treatment options for metastatic melanoma].
    Tietze JK; Berking C
    Dtsch Med Wochenschr; 2014 Jul; 139(28-29):1462-7. PubMed ID: 24983194
    [No Abstract]   [Full Text] [Related]  

  • 3. The Future of Molecular Analysis in Melanoma: Diagnostics to Direct Molecularly Targeted Therapy.
    Akabane H; Sullivan RJ
    Am J Clin Dermatol; 2016 Feb; 17(1):1-10. PubMed ID: 26518880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dividing and conquering: controlling advanced melanoma by targeting oncogene-defined subsets.
    Flaherty KT
    Clin Exp Metastasis; 2012 Oct; 29(7):841-6. PubMed ID: 22661223
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Ponti G; Manfredini M; Greco S; Pellacani G; Depenni R; Tomasi A; Maccaferri M; Cascinu S
    Anticancer Res; 2017 Dec; 37(12):7043-7048. PubMed ID: 29187493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutation scanning of BRAF, NRAS, KIT, and GNAQ/GNA11 in oral mucosal melanoma: a study of 57 cases.
    Lyu J; Wu Y; Li C; Wang R; Song H; Ren G; Guo W
    J Oral Pathol Med; 2016 Apr; 45(4):295-301. PubMed ID: 26399561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
    Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
    Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutation stability in primary and metastatic melanoma: what we know and what we don't.
    Varada S; Mahalingam M
    Histol Histopathol; 2015 Jul; 30(7):763-70. PubMed ID: 25585249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases.
    Niessner H; Forschner A; Klumpp B; Honegger JB; Witte M; Bornemann A; Dummer R; Adam A; Bauer J; Tabatabai G; Flaherty K; Sinnberg T; Beck D; Leiter U; Mauch C; Roesch A; Weide B; Eigentler T; Schadendorf D; Garbe C; Kulms D; Quintanilla-Martinez L; Meier F
    Cancer Med; 2013 Feb; 2(1):76-85. PubMed ID: 24133630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular targeted approaches for advanced BRAF V600, N-RAS, c-KIT, and GNAQ melanomas.
    Ponti G; Pellacani G; Tomasi A; Loschi P; Luppi G; Gelsomino F; Longo C
    Dis Markers; 2014; 2014():671283. PubMed ID: 24591764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted therapies for cutaneous melanoma.
    Kee D; McArthur G
    Hematol Oncol Clin North Am; 2014 Jun; 28(3):491-505. PubMed ID: 24880943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment of metastatic melanoma with BRAF inhibitors].
    Hafner C
    Hautarzt; 2011 Sep; 62(9):696-8. PubMed ID: 21863388
    [No Abstract]   [Full Text] [Related]  

  • 13. The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort.
    Ekedahl H; Cirenajwis H; Harbst K; Carneiro A; Nielsen K; Olsson H; Lundgren L; Ingvar C; Jönsson G
    Br J Dermatol; 2013 Nov; 169(5):1049-55. PubMed ID: 23855428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRAF, NRAS, KIT, TERT, GNAQ/GNA11 mutation profile analysis of head and neck mucosal melanomas: a study of 42 cases.
    Öztürk Sari Ş; Yilmaz İ; Taşkin OÇ; Narli G; Şen F; Çomoğlu Ş; Firat P; Bİlgİç B; Yilmazbayhan D; Özlük Y; Büyükbabanİ N
    Pathology; 2017 Jan; 49(1):55-61. PubMed ID: 27914687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Melanoma patients in a phase I clinic: molecular aberrations, targeted therapy and outcomes.
    Henary H; Hong DS; Falchook GS; Tsimberidou A; George GC; Wen S; Wheler J; Fu S; Naing A; Piha-Paul S; Janku F; Kim KB; Hwu P; Kurzrock R
    Ann Oncol; 2013 Aug; 24(8):2158-65. PubMed ID: 23576709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment implications of the emerging molecular classification system for melanoma.
    Romano E; Schwartz GK; Chapman PB; Wolchock JD; Carvajal RD
    Lancet Oncol; 2011 Sep; 12(9):913-22. PubMed ID: 21349766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequencies of KIT and GNAQ mutations in acral melanoma.
    Puntervoll HE; Molven A; Akslen LA
    J Cutan Pathol; 2014 Nov; 41(11):893-4. PubMed ID: 25363280
    [No Abstract]   [Full Text] [Related]  

  • 18. [Melanoma: from molecular studies to the treatment breakthrough].
    Imianitov EN
    Arkh Patol; 2013; 75(5):63-72. PubMed ID: 24341237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials.
    Lovly CM; Dahlman KB; Fohn LE; Su Z; Dias-Santagata D; Hicks DJ; Hucks D; Berry E; Terry C; Duke M; Su Y; Sobolik-Delmaire T; Richmond A; Kelley MC; Vnencak-Jones CL; Iafrate AJ; Sosman J; Pao W
    PLoS One; 2012; 7(4):e35309. PubMed ID: 22536370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Melanoma.
    Schadendorf D; Fisher DE; Garbe C; Gershenwald JE; Grob JJ; Halpern A; Herlyn M; Marchetti MA; McArthur G; Ribas A; Roesch A; Hauschild A
    Nat Rev Dis Primers; 2015 Apr; 1():15003. PubMed ID: 27188223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.